---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-015057"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:01:42.707752+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026

## Summary
- Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).
- ZYNLONTA net product revenue $16.4M in Q4 and $69.3M for FY 2024, roughly flat vs prior year.
- Cash $250.9M at Dec 31, 2024; runway into H2 2026 after $97.4M May 2024 offering.
- LOTIS-5 Phase 3 confirmatory trial enrollment completed Dec 2024; data update expected late 2025.
- LOTIS-7 Phase 1b: 94% best ORR and 72% CR in r/r DLBCL; dose expansion enrollment completing Q2 2025.

## SEC filing metadata
- accession: 0001628280-25-015057
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/0001628280-25-015057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/adc-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-015057
- JSON: https://secwatch.observer/filing/0001628280-25-015057.json
- Plain text: https://secwatch.observer/filing/0001628280-25-015057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.